Affordable semaglutide syringes starting at Rs 350 could improve access to diabetes and obesity treatment while supporting ...

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for ...

The Nifty Pharma index rose 1.4% on 8 June, defying the broader market selloff, supported by heavyweight stocks like JB ...

Alkem Laboratories shares jumped over 5% after Q4FY26 results beat estimates. Brokerages remain positive on strong guidance, ...

Alkem noted that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market ...

The block deal worth Rs 930 crore in Alkem Laboratories today follows reports that the Samprada and Nanhamati Family Trust ...

The launch comes as India grapples with rising diabetes and obesity cases, offering patients another treatment option ...

Alkem launches affordable semaglutide pre-filled syringes for diabetes and obesity, expanding treatment options with multiple ...

Alkem Laboratories shares drop over 1% after ₹930 crore promoter stake sale, with trading volatility observed throughout the ...

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Alkem Laboratories Limited (NSEI:ALKEM), with a market cap of ₹235.10B, are often out of the ...

Mumbai: Pharmaceutical major Alkem Laboratories Limited on Thursday reported a 27.7 per cent decline in consolidated net ...

Alkem Laboratories sees block deal for up to 1.5% stake at floor price ₹5200 per share, Q4FY26 revenue up 14.6%. Shares of ...